HiberGene Overview

  • Founded
  • 2009

Founded
  • Status
  • Private

  • Employees
  • 25

Employees
  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $1.59M

  • Investors
  • 9

HiberGene General Information

Description

Developer of real-time molecular diagnostic tests designed to test for the direct detection of human infectious diseases. The company's tests utilize loop-mediated isothermal amplification, performed on a small, portable, and low-cost platform, enabling clinicians to diagnose their disease in near-patient settings such as clinical laboratories, emergency rooms, and delivery wards producing.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Primary Office
  • Block 2, Bracken Business Park
  • Sandyford
  • Dublin D18 RR24
  • Ireland
+353 (01) 000 0000

HiberGene Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

HiberGene Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC 21-Dec-2020 $1.59M 000.00 00.000 Completed Generating Revenue
7. Grant Cancelled Generating Revenue
6. Grant 20-May-2020 00.000 000.00 Completed Generating Revenue
5. Later Stage VC 21-Dec-2018 00.000 000.00 000.00 Completed Generating Revenue
4. Later Stage VC (Series B) 12-Apr-2017 00.000 00.00 000.00 Completed Generating Revenue
3. Grant 10-Feb-2016 000.00 00.000 Completed Generating Revenue
2. Later Stage VC (Series A) 01-Dec-2014 $2.64M $2.64M 00.000 Completed Generating Revenue
1. Spin-Off 01-Jan-2009 Completed Generating Revenue
To view HiberGene’s complete valuation and funding history, request access »

HiberGene Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
Ordinary 0,000 00.000000 00000.00 00000.00 00 00000.00 00.00
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 000 00.000000 00000.00 00000.00 00 00000.00 0.000
Ordinary 1,151 $0.012069 $1486.28 $1486.28 1x $1486.28 8.74%
Ordinary 20 $0.012069 $1474.45 $1474.45 1x $1474.45 0.15%
To view HiberGene’s complete cap table history, request access »

HiberGene Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of real-time molecular diagnostic tests designed to test for the direct detection of human infectious diseases
Diagnostic Equipment
Dublin, Ireland
25 As of 2022
000.00
0.000 0000-00-00
0000000000 0 000.00

000000

ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse
0000000000 000000000
Quebec, Canada
000 As of 0000
0000 0000-00-00
000000&0

00 000

laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000000000 000000000
Lexington, MA
000 As of 0000
00000
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

HiberGene Competitors (35)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GenePOC Corporate Backed or Acquired Quebec, Canada 000 000000&0
00 0000000000 Formerly VC-backed Lexington, MA 000 00000 00000000000 00000
000000000000 Formerly VC-backed Seoul, South Korea 000 000.00 00000000 000.00
0000000 0000000000 Corporate Backed or Acquired Carlsbad, CA 000 0000 000000&0 0000
00000000000 Corporation San Diego, CA 0000 00000000
You’re viewing 5 of 35 competitors. Get the full list »

HiberGene Executive Team (11)

Name Title Board Seat Contact Info
David Corr Ph.D Chief Executive Officer & Board Member
Peter Kidney Co-Founder, Chief Financial Officer & Board Member
Gary Keating Ph.D Chief Technology Officer & Clinical Advisor
Joe Kidney MD Clinical Advisor
Peter Coyle MD Clinical Advisor
You’re viewing 5 of 11 executive team members. Get the full list »

HiberGene Board Members (11)

Name Representing Role Since
David Corr Ph.D HiberGene Chief Executive Officer & Board Member 000 0000
James Murray HiberGene Co-Chairman 000 0000
Meinhard Schmidt Self Co-Chairman 000 0000
Peter Kidney HiberGene Co-Founder, Chief Financial Officer & Board Member 000 0000
Tom Noonan Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

HiberGene Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

HiberGene Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Shackleton Ventures PE/Buyout Minority 000 0000 000000 0
Cantor Fitzgerald Investment Bank Minority 000 0000 000000 0
MedCaptain VC-Backed Company Minority 000 0000 000000 0
Ruffena Capital Growth/Expansion Minority 000 0000 000000 0
SyndicateRoom Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »